2011 Symposium Agenda
13th Annual Lynn Sage Breast Cancer Breakout Sessions

The following meal symposia are complimentary for participants of the Lynn Sage Breast Cancer Symposium. Session seating is limited and is on first-come, first-seated basis.

Thursday September 15, 2011
Her2 Positive Breast Cancer: How to Optimize Therapy
Time: 11:30 am
Faculty: Hope Rugo, MD; Harold Burstein, MD, PhD
Moderator: William Gradishar, MD

Objectives
1) Identify optimal strategies for the anti-HER2 therapy in metastatic setting

2) Describe controversy regarding data suggesting benefit to anti-HER2 therapy in non-expressing tumors

3) Cite emerging data with novel anti HER2 agents

Friday September 16, 2011
Complex Local Therapy Issues in Breast Cancer
Time: 6:30 am
Faculty: Mary Gemignani, MD; William Small JR, MD
Moderator: Monica Morrow, MD

Objectives
1) Describe role of mastectomy in patients with de novo metastatic breast cancer

2) Discuss the data supporting a radiation boost for patients undergoing lumpectomy and adjuvant radiation therapy

3) Explain the issues related to what constitutes an adequate surgical margin in patients with invasive or non-invasive breast cancer

4) Intrepret the clinical impact of post-mastectomy radiation therapy in patients with node –negative or positive breast cancer

Friday September 16, 2011
Managing Aggressive Metastatic Breast Cancer
Time: 12:15 PM
Faculty: William Gradishar, MD; Mary Cianfrocca, DO
Moderator: William Gradishar, MD

Objectives
1) Describe the difference in biology between TNBC and other subtypes

2) Explain the efficiency of novel agents to treat triple negative breast cancer and chemotherapy-refractory metastatic breast cancer.

Saturday September 17, 2011
Applying Gene-Signatures to Patient Management Issues
Time: 11:30 am
Faculty: William Gradishar, MD; Ann Partridge, MD, MPH
Moderator: William Gradishar, MD

Objectives
1) Explain the difference in gene signatures assays currently available

2) Discuss the clinical data supporting the use of these assay to define prognosis and benefit from chemotherapy in node negative and positive disease

The Following Statements Apply To Each Breakout Session:

Accreditation Statement
The Northwestern University’s Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The Northwestern University’s Feinberg School of Medicine designates each of the four breakout sessions for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.